Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial
Category: #health  By Saipriya Iyer  Date: 2019-11-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial

Anelixis Therapeutics has reportedly concluded its testing of an investigational antibody, AT-1501, in a Phase 1 clinical trial in healthy volunteers as well as eight patients suffering from amyotrophic lateral sclerosis (ALS). The company further announced that it has raised enough funds to advance to AT-1501’s Phase 2 clinical trial.

The Phase 1 trial came out with a positive result as AT-1501 was well-tolerated at every dose that was tested. The processing of the drug inside the body, which is also called pharmacokinetics, was the same as was predicted by the researchers. The details of the study are to be presented at scientific meetings expected held in the future.

The company anticipates this data to support more clinical studies regarding ALS as well as other disorders to further analyze the tolerability and safety of AT-1501, including other clinical parameters like potential biomarkers.

AT-1501 happens to be an investigational antibody targeting CD40 ligand (CD40L), which is essentially a kind of protein on the surface of white blood cells causing inflammation. The U.S. Food and Drug Administration has given this therapy the designation of an orphan drug. 

The ALS Therapy Development Institute (ALS TDI) has developed AT-1501 with the help of numerous ALS organizations such as ALS Finding a Cure, ALS Association and ALS ONE. The Phase 1 trial was funded by ALS Association by over $1 million.

CEO and Founder of Anelixis, Steven Perrin, Ph.D., stated that allograft rejection, autoimmune diseases and ALS represent large unmet medical needs and the company is looking forward to exploring AT-1501’s potential value as diligently and quickly as possible. Advancement of the drug into a strong clinical research program will be providing significant potential opportunities for all the patients both in the ALS and the diabetes communities, he added.

 

Source Credits- https://alsnewstoday.com/2019/11/21/anelixis-therapeutics-als-therapy-at-1501-phase-2-clinical-trial/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
New Medtronic Micra AV pacemaker receives approval from the U.S. FDA
By Saipriya Iyer

Medtronic plc, a renowned US-based medical device company, reportedly announced that its Micra AV pacemaker has received approval from the U.S. FDA. The Medtronic Micra AV is the world’s smallest pacemaker with A...

Health Canada grants two DIN to new Tetra Bio-pharma OTC products
Health Canada grants two DIN to new Tetra Bio-pharma OTC products
By Saipriya Iyer

Tetra Bio-pharma, a renowned Canadian biopharmaceutical company, reportedly announced that Health Canada, the regulatory health authority of Canada, has granted two new DIN (Drug Identification Numbers) for the first O...

Digital River & Magento team-up to create customized commerce solution
Digital River & Magento team-up to create customized commerce solution
By Saipriya Iyer

Digital River, a renowned global ecommerce facilitator for well-known and fast-growing brands, has reportedly signed a new strategic partnership deal with Magento, a leading provider of commerce innovations to retailer...